Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOMENTUM-1: [177Lu]Lu-DOTATATE in Progressive Intracranial Meningioma
NCT06955169Phase 2Recruiting
- Sponsor
- RTOG Foundation
- Start
- Aug 2025
- Primary completion
- Aug 2029
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in meningioma comparing [177Lu]Lu-DOTATATE with Control (Standard of Care) (2 arms). Primary endpoint: Progression-Free Survival at 4 years. Started Aug 2025; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
meningioma
Beyond the preview
Go deeper on NCT06955169.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06955169.